OpenAI has launched GPT-4b micro, an AI model developed with longevity startup Retro Biosciences to accelerate protein engineering. Unlike chatbots, it focuses on biological sequences and 3D structures.

The model redesigned two Yamanaka factors- proteins that convert adult cells into stem cells, showing 50-fold higher efficiency in lab tests and improved DNA repair. Older cells acted more youthful, potentially shortening trial-and-error in regenerative medicine.

AI-designed proteins could speed up drug development and allow longevity startups to rejuvenate cells safely and consistently. The work also opens new possibilities in synthetic biology beyond natural evolution.

OpenAI emphasised that the research is still early and lab-based, with clinical applications requiring caution. Transparency is key, as the technology's power to design potent proteins quickly raises biosecurity considerations.